The global nefopam hydrochloride injection market size is calculated at USD 129 billion in 2025 and is forecasted to reach around USD 246.30 billion by 2034, accelerating at a CAGR of 7.45% from 2025 to 2034. The Europe market size surpassed USD 48.02 billion in 2024 and is expanding at a CAGR of 7.58% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Nefopam Hydrochloride Injection Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Nefopam Hydrochloride Injection Market Revenue and Volume Forecast, by Dosage Form / Presentation
8.1.1. Injection / parenteral (ampoules 20 mg/2 mL; vials)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Oral solid (tablets/capsules)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Oral liquid (syrup)
8.1.3.1. Market Revenue and Volume Forecast
9.1. Nefopam Hydrochloride Injection Market Revenue and Volume Forecast, by Injectable Presentation / Format
9.1.1. Single-dose glass ampoules (2 mL ampoules typical)
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Multi-dose vials (if marketed in region)
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Prefilled syringes / ready-to-use formats (emerging/rare)
9.1.3.1. Market Revenue and Volume Forecast
10.1. Nefopam Hydrochloride Injection Market Revenue and Volume Forecast, by Route of Administration / Use Case
10.1.1. Intravenous (IV bolus / slow IV injection)
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intramuscular (IM)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Perioperative/postoperative analgesia protocols
10.1.3.1. Market Revenue and Volume Forecast
11.1. Nefopam Hydrochloride Injection Market Revenue and Volume Forecast, by End-User / Buyer
11.1.1. Hospitals & surgical centers (primary purchasers)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Ambulance/emergency services (limited)
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Retail pharmacies (where outpatient prescription is allowed)
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Government / public health procurement (some markets)
11.1.4.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.1.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.1.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.1.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.1.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.1.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.1.6.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.1.6.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.2.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.2.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.2.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.2.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.2.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.2.6.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.2.6.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.2.7.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.2.7.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.2.8.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.2.8.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.3.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.3.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.3.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.3.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.3.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.3.6.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.3.6.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.3.7.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.3.7.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.3.8.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.3.8.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.4.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.4.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.4.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.4.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.4.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.4.6.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.4.6.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.4.7.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.4.7.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.4.8.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.4.8.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.5.5.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.5.5.4. Market Revenue and Volume Forecast, by End-User / Buyer
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Dosage Form / Presentation
12.5.6.2. Market Revenue and Volume Forecast, by Injectable Presentation / Format
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration / Use Case
12.5.6.4. Market Revenue and Volume Forecast, by End-User / Buyer
13.1. Biocodex (Acupan®)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial PerDosage Form / Presentationance
13.1.4. Recent Initiatives
13.2. Polpharma
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial PerDosage Form / Presentationance
13.2.4. Recent Initiatives
13.3. PMC Isochem
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial PerDosage Form / Presentationance
13.3.4. Recent Initiatives
13.4. Arene Lifesciences
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial PerDosage Form / Presentationance
13.4.4. Recent Initiatives
13.5. CF Pharma
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial PerDosage Form / Presentationance
13.5.4. Recent Initiatives
13.6. Emcure Pharmaceuticals
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial PerDosage Form / Presentationance
13.6.4. Recent Initiatives
13.7. Micro Labs Limited
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial PerDosage Form / Presentationance
13.7.4. Recent Initiatives
13.8. Maiden Group
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial PerDosage Form / Presentationance
13.8.4. Recent Initiatives
13.9. PRG Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial PerDosage Form / Presentationance
13.9.4. Recent Initiatives
13.10. Sai Life Sciences
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial PerDosage Form / Presentationance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description